UK report on interpreting patient-reported outcomes from clinical trials

Researchers from the University of London, AstraZeneca and GlaxoSmithKline have developed a set of questions for practicing clinicians to consider when reviewing the results of patient-reported outcome (PROs) measures and effectiveness of medical procedures.

Researchers from the University of London, AstraZeneca and GlaxoSmithKline have developed a set of questions for practicing clinicians to consider when reviewing the results of patient-reported outcome (PROs) measures and effectiveness of medical procedures.

Different models of presenting and interpreting PROs discussed in the paper are based on the type of therapy design, patient withdrawal and the selected study population. Although the worked example is a respiratory questionnaire, the principles derived from this study are also applicable to other symptom-based questionnaires.

From the report: ‘For the practicing clinician, the most important consideration is individualising treatment (and treatment goals). To inform such treatment, clinicians need to critically review PRO data. The hope is that the questions posed here will help to build a framework for this critical review’.

Video summary:

Read the report

 

 

 

Related Articles

UK Apply outcomes to assess – and address – inequality in Europe’s heath care systems

High quality does not always equate to high value in healthcare. Teasing out what works is essential to making Europe’s healthcare systems sustainable for the future

9 January 2017

Call for healthcare to be assessed on outcomes not activity

As static budgets come head-to-head with spiralling demand, Europe must find a way to get more out of its substantial investment in health. A Science|Business event hears the answer lies in measuring patient outcomes to understand what works

10 January 2017